Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00650104
First received: March 27, 2008
Last updated: May 2, 2013
Last verified: April 2013
Results First Received: February 24, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Parkinson Disease
Intervention: Drug: Ropinirole XL (formerly CR)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Study 101468/196 (this study; NCT#00650104) was an open-label, ropinirole XL (2-24 mg/day), continuation study for participants with Parkinson's Disease who previously completed Studies 167 or 164. Treatment was originally designed to continue for 3 years, but it was extended until ropinirole XL became commercially available in each study country.

Reporting Groups
  Description
Ropinirole XL Up-titration: some participants from Study 167 started at 2 milligrams (mg) ropinirole XL once daily. Then, depending on the response/tolerance of each participant, the dose was increased in 1 mg weekly increments to 4 mg, then 2 mg weekly increments up to 12 mg, and in either 2 mg or 4 mg weekly increments up to 24 mg to the clinical optimum dose. Other Study 167 participants were increased in 2 mg weekly increments up to 8 mg and then 4 mg weekly increments up to 24 mg. Study 164 particiapnts who were on an optimal dose of ropinirole XL could go straight into the long-term treatment period, and those who were receiving ropinirole IR could be switched to the corresponding XL dose. Long-term treatment: participants received study medication until market availability of ropinirole XL. After market availability, participants would undergo a 1-week down-titration period; after protocol amendment #4 approval, participants could switch directly to the market-available dose.

Participant Flow:   Overall Study
    Ropinirole XL  
STARTED     83  
COMPLETED     42  
NOT COMPLETED     41  
Adverse Event                 17  
Death                 2  
Withdrawal by Subject                 11  
Physician Decision                 7  
Lost to Follow-up                 1  
Non-compliance                 2  
Sponsor Terminated Dosing                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Ropinirole XL Up-titration: some participants from Study 167 started at 2 milligrams (mg) ropinirole XL once daily. Then, depending on the response/tolerance of each participant, the dose was increased in 1 mg weekly increments to 4 mg, then 2 mg weekly increments up to 12 mg, and in either 2 mg or 4 mg weekly increments up to 24 mg to the clinical optimum dose. Other Study 167 participants were increased in 2 mg weekly increments up to 8 mg and then 4 mg weekly increments up to 24 mg. Study 164 particiapnts who were on an optimal dose of ropinirole XL could go straight into the long-term treatment period, and those who were receiving ropinirole IR could be switched to the corresponding XL dose. Long-term treatment: participants received study medication until market availability of ropinirole XL. After market availability, participants would undergo a 1-week down-titration period; after protocol amendment #4 approval, participants could switch directly to the market-available dose.

Baseline Measures
    Ropinirole XL  
Number of Participants  
[units: participants]
  83  
Age  
[units: years]
Mean ± Standard Deviation
  65.1  ± 9.85  
Gender  
[units: participants]
 
Female     37  
Male     46  
Race/Ethnicity, Customized  
[units: participants]
 
Caucasian     74  
Hispanic     6  
Black     1  
Asian     1  
Other     1  
Weight [1]
[units: kilograms¬†(kg)]
Mean ± Standard Deviation
  79.24  ± 16.8  
[1] Weight was captured during collection of demography data at baseline.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Unified Parkinson’s Disease (PD) Rating Scale (UPDRS) Total Activities of Daily Living Scores (Intent-to-Treat Population)   [ Time Frame: Screening; Week 4; Months 3, 9, 15, 21, 27, 33, 39, 45, 51, 57, 63, 69, 75, and 78 ]

2.  Primary:   Number of Participants With the Indicated Number of Adverse Events (AEs)   [ Time Frame: Every study visit from baseline to market availability (Month 78) ]

3.  Secondary:   Unified Parkinson’s Disease Rating Scale (UPDRS) Total Activities of Daily Living Score (Responder Population)   [ Time Frame: Screening; Months 3, 9, 15, 27, and 78 ]

4.  Secondary:   Unified Parkinson’s Disease Rating Scale (UPDRS) Total Activities of Daily Living Scores (Maintained Responder Population)   [ Time Frame: Screening; Months 3, 9, 15, 27, and 78 ]

5.  Secondary:   Unified Parkinson’s Disease Rating Scale (UPDRS) Motor Examination Score (ITT Population)   [ Time Frame: Screening and Month 78 ]

6.  Secondary:   Unified Parkinson’s Disease Rating Scale (UPDRS) Motor Examination Score (Reponder Population)   [ Time Frame: Screening and Month 78 ]

7.  Secondary:   Unified Parkinson’s Disease Rating Scale (UPDRS) Motor Examination Score (Maintained Responder Population)   [ Time Frame: Screening and Month 78 ]

8.  Secondary:   Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (ITT Population)   [ Time Frame: Week 2, Month 12, Month 78 ]

9.  Secondary:   Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Responder Population)   [ Time Frame: Week 2, Month 12, Month 78 ]

10.  Secondary:   Number of Participants With the Indicated Responses for CGI Global Impression (CGI-I) (Maintained Responder Population)   [ Time Frame: Week 2, Month 12, Month 78 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: GSK Response Center
Organization: GlaxoSmithKline
phone: 866-435-7343


No publications provided by GlaxoSmithKline

Publications automatically indexed to this study:

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00650104     History of Changes
Other Study ID Numbers: 101468/196
Study First Received: March 27, 2008
Results First Received: February 24, 2010
Last Updated: May 2, 2013
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Norway: Norwegian Medicines Agency
Netherlands: Medicines Evaluation Board (MEB)
United States: Food and Drug Administration